期刊文献+

猕猴多次皮下注射重组人血小板生成素后药代动力学,血小板计数和抗体的变化 被引量:5

Pharmacokinetics, peripheral platelet counts and anti-thrombo- poietin-antibodies after multi-dosing of recombinant human thrombopoietin in macaca mulatta
暂未订购
导出
摘要 研究猕猴多次 sc重组人血小板生成素(rh TPO) 2 μg· kg-1· d-1× 2 0 d或保护剂白蛋白后药代动力学 ,外周血小板计数及血清 TPO抗体变化 ;通过猴血清对 TD- 3细胞依赖 TPO增殖效应的影响评价抗体性质 .酶联免疫法测定血清 rh TPO浓度表明在第 1 ,7和 2 0次注药后 cmax和 AUC0 -τ随注药次数增加明显降低 ,而 Tp 提前 ,提示 TPO存在时间依赖性非线性过程 .血小板于 d5开始增高 ,d 1 4达峰值 ,d 2 0仍保持较高水平 (2 97±2 7) % .于 d 9- 1 1出现低滴度抗 TPO抗体 ,d 2 1达最高滴度 (1∶ 2 5- 1∶ 1 2 5) .sc TPO和白蛋白后猴血清对 TD- 3依赖 TPO增殖效应均有轻微抑制作用 ,抑制曲线呈非中和抗体性质 . Drug concentration, peripheral platelet count and anti-thrombopoietin(TPO)-antibodies were studied after sc multi-dosing of recombinant human TPO(rhTPO, 2 μg·kg -1·d -1×20 d) in macaca mulatta and compared with vehicle (albumin) control. The nature of antibodies was studied by means of the inhibitory effect of anti-sera on the TPO-dependent proliferation of TD-3 cells in vitro. Concentration-time curves of TPO determined by ELISA demonstrated that the c max and AUC 0-τ following the 1st, the 7th, and the 20th dosing of rhTPO significantly decreased with dosing (P<0.05). Values of c max were (3.49±1.45), (2.84±1.52), and (1.18±0.24) μg·L -1; while AUC 0-τ were (37.5±13.3), (30.1±15.6), and (13.8±1.5) μg·h·L -1, respectively. Time to peak (T p) brought forward from (4.7±1.2) and (3.3±1.2) to (1.7±0.6) h, respectively. Peripheral platelet counts began to increase on d 5, achieved maximal (404±92)% on d 14, and maintained at high levels (297±27)% on d 20. Low titers of anti-TPO antibodies were detected on d 9-11 and reached their maximal levels of 1∶25-1∶125 on d 21. Inhibitory effect of sera on TPO dose-dependent proliferation of TD-3 cells was not related to treatment (TPO or albumin) or anti-TPO antibody titers, and the dose-response curve was not competitive. The results suggest that there be time-dependent non-linear pharmacokinetics after multi-dosing of rhTPO. Platelet counts was maintained at high level during multi-dosing. Low titer of anti-TPO antibodies was detected, but were not neutralizing antibody.
出处 《中国药理学与毒理学杂志》 CSCD 北大核心 2000年第3期227-231,共5页 Chinese Journal of Pharmacology and Toxicology
基金 国家自然科学基金重点资助项目! (39930 180 )
关键词 重组蛋白 血小板生成素 药代动力学 猕猴 recombinant protein thrombopoietin pharmacokinetics enzyme-linked immuno-sorbent assay platelet count antibodies Macaca mulatta
  • 相关文献

参考文献2

二级参考文献2

  • 1Bartley T D,Cell,1994年,77卷,1117页
  • 2deSauvageFJ,Nature,1994年,369卷,533页

共引文献8

同被引文献70

  • 1林缨.肿瘤坏死因子检测技术的进展[J].药物分析杂志,1996,16(5):346-352. 被引量:1
  • 2Shinjo K,Takeshita A,Nakamura S,et al.Serum thrombopoietin levels in patients correlate inversely with platelet counts during chemotherapy-induced thrombocytopenia[J].Leukemia,1998,12:295-300.
  • 3Saroj VR,Claire FV,Carlos BR,et al.Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer[J].Ann Intern Med,2000; 132:364-368.
  • 4Wolff SN,Herzig R,Lynch J,et al.Recombinant human thrombopoietin (rhTPO) after autologous bone marrow transplantation:a phase I pharmacoknetic and phamacodynamic study[J].Bone Marrow Transplantat,2001 ;27:261-268.
  • 5Haubner R, Wester HJ, Burkhart F, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics[J]. J Nucl Med,2001,42(2): 326.
  • 6Yu H, Raymonda JW, McMahon TM, et al. Detection of biological threat agents by immunomagnetic microsphere-based solid phase fluorogenic-and electro-chemiluminescence [ J ]. Biosens Bioelectron,2000,14 (10-11):829.
  • 7Geary RS, Yu RZ, Watanabe T, et al. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl ) modified antisense oligonucleotide: comparison across species[ J ]. Drug Metab Dispos ,2003,31(11): 1419.
  • 8罗建辉.关于生物制品活性的思考[J].药品技术审评论坛,2003,(3):782-782.
  • 9Stute N, Furman WL, Schell M, et al. Pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in children after intravenous and subcutaneous administration[ J]. J Pharm Sci, 1995, 84 (7) : 824.
  • 10Sargent JM. The use of the MTT assay to study drug resistance in fresh tumour samples[ J ]. Recent Results Cancer Res ,2003,161:13.

引证文献5

二级引证文献76

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部